retatrutide description Buy in the UK RETATRUTIDE (RETA)

Front Endocrinol (2021) 12:721135

When caloric intake drops significantly, the thyroid may reduce hormone output as a protective mechanism

That said, the side effect profile overlaps significantly with GLP-1 agonistsGI symptoms like nausea, vomiting, and diarrhea are still common, especially during dose escalation

At 24 weeks, liver fat reduction was: 1 mg : 42.9% 4 mg : 57.0% 8 mg : 81.4% 12 mg : 82.4% Placebo : +0.3% These findings highlight retatrutides versatility across various research applications, from metabolic studies to liver health investigations

Rotating between sites helps prevent injection site reactions from developing

Regulatory Status: Retatrutide is an investigational drug, still in Phase 3 clinical trials, and not yet approved by regulatory bodies like the FDA